# EDGAR Filing Document

**Accession Number:** 0001533743
**File Stem:** 0001493152-25-013108
**Filing Date:** 2025-9
**Character Count:** 6988
**Document Hash:** de67a9c9631188b9f0ef644ec4d97fed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-013108.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001493152-25-013108

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250911

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20250911

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Processa Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001533743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 451539785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39531
- **FILM NUMBER:** 251309722

**BUSINESS ADDRESS:**
- **STREET 1:** 601 21ST STREET, SUITE 300
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32960
- **BUSINESS PHONE:** 443-776-3133

**MAIL ADDRESS:**
- **STREET 1:** 601 21ST STREET, SUITE 300
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32960

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Heatwurx, Inc.
- **DATE OF NAME CHANGE:** 20111028

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 11, 2025**

**PROCESSA PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39531** | **45-1539785** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **601 21st Street, Suite 300 Vero Beach, FL** | **32960** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (772) 453-2899**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | PCSA | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07** **Submission of Matters to a Vote of Security Holders.**

On September 11, 2025, the Company held a Special Meeting of Shareholders (the "Special Meeting"). A total of 50,349,149 shares of common stock were entitled to vote as of August 7, 2025, the record date for the Special Meeting. Present at the Special Meeting in person or by proxy were holders of 17,127,838 shares of common stock of the Company, representing at least one-third (1/3) of the voting power of the common stock of the Company outstanding and entitled to vote, constituting a quorum for the transaction of business.

The shareholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the shareholders and the final voting results of each such proposal.

&nbsp;&nbsp;&nbsp;&nbsp;1. Approval
 of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized
 shares of common stock from 100,000,000 shares to 1,000,000,000 (the "Charter Proposal"):

<u>Shares</u> <br> <u>For</u> <u>Against</u> <u>Abstain</u> <br> 13,706,276 3,029,091 392,471

&nbsp;&nbsp;&nbsp;&nbsp;2. Approval
 of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation,
 to effect a reverse stock split of the Company's outstanding common stock, $0.0001 par value per share, at a ratio of not less
 than 1-for-2 and not more than 1-for-50, such ratio to be determined in the sole discretion of the Company's Board of Directors,
 without a corresponding reduction in the Company's authorized shares, and to be effective upon a date determined by the Board
 of Directors no later than December 31, 2026 (the "Reverse Stock Split Proposal"):

<u>Shares</u> <br> <u>For</u> <u>Against</u> <u>Abstain</u> <br> 13,887,533 3,126,720 113,585

&nbsp;&nbsp;&nbsp;&nbsp;3. Approval
 of an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive
 Plan to increase the number of shares available for issuance under the Plan (the "OIP
 Proposal"):

<u>Shares</u> <br> <u>For</u> <u>Against</u> <u>Abstain</u> <br> 13,649,262 3,425,245 53,331

&nbsp;&nbsp;&nbsp;&nbsp;4. Approval
 of an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if
 there are insufficient votes in favor of the Charter Proposal, the Reverse Stock Split Proposal and/or the OIP Proposal or to establish
 a quorum (the "Adjournment Proposal"):

<u>Shares</u> <br> <u>For</u> <u>Against</u> <u>Abstain</u> <br> 14,039,730 2,563,581 524,527

Although the Adjournment Proposal was approved, the adjournment of the Special Meeting was not necessary because the shareholders approved the Charter Proposal, the Reverse Stock Split Proposal, and the OIP Proposal.

**Item 9.01(d)** **Financial Statements and Exhibits**

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL documents)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PROCESSA PHARMACEUTICALS, INC.** | **PROCESSA PHARMACEUTICALS, INC.** |
| Date: September 12, 2025 | By: | */s/ Russell Skibsted* |
|  |  | Russell Skibsted |
|  |  | Chief Financial Officer |

---